Literature DB >> 10189977

Fluoxetine versus placebo for the marijuana use of depressed alcoholics.

J R Cornelius1, I M Salloum, R F Haskett, J G Ehler, P J Jarrett, M E Thase, J M Perel.   

Abstract

The aim of this analysis was to evaluate the efficacy of the SSRI antidepressant fluoxetine versus placebo for the marijuana use of depressed alcoholics. There are no previous reports involving and SSRI antidepressant for marijuana abuse. This analysis involved a subsample of 22 depressed alcoholic marijuana users out of a total of 51 depressed alcoholics. The entire sample was involved in a 12-week double-blind, placebo-controlled study evaluating the efficacy of fluoxetine versus placebo in depressed alcoholics. During the course of the trial, the cumulative number of marijuana cigarettes used was almost 20 times as high in the placebo group as in the fluoxetine group. Also, the number of days of marijuana use during the study was five times higher in the placebo group than in the fluoxetine group. These data suggest efficacy for fluoxetine in decreasing marijuana use of depressed alcoholics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10189977     DOI: 10.1016/s0306-4603(98)00050-1

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  16 in total

Review 1.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

2.  Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.

Authors:  Jack R Cornelius; Oscar G Bukstein; Antoine B Douaihy; Duncan B Clark; Tammy A Chung; Dennis C Daley; D Scott Wood; Sandra J Brown
Journal:  Drug Alcohol Depend       Date:  2010-06-23       Impact factor: 4.492

3.  A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Authors:  Frances R Levin; John Mariani; Daniel J Brooks; Martina Pavlicova; Edward V Nunes; Vito Agosti; Adam Bisaga; Maria A Sullivan; Kenneth M Carpenter
Journal:  Addiction       Date:  2013-03-21       Impact factor: 6.526

4.  The Pittsburgh Girls Study: overview and initial findings.

Authors:  Kate Keenan; Alison Hipwell; Tammy Chung; Stephanie Stepp; Magda Stouthamer-Loeber; Rolf Loeber; Kathleen McTigue
Journal:  J Clin Child Adolesc Psychol       Date:  2010

5.  Vilazodone for cannabis dependence: A randomized, controlled pilot trial.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese Killeen; Karen J Hartwell; Susan J Simonian
Journal:  Am J Addict       Date:  2015-12-20

6.  A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.

Authors:  Kenneth M Carpenter; David McDowell; Daniel J Brooks; Wendy Y Cheng; Frances R Levin
Journal:  Am J Addict       Date:  2009 Jan-Feb

Review 7.  Marijuana neurobiology and treatment.

Authors:  Ahmed Elkashef; Frank Vocci; Marilyn Huestis; Margaret Haney; Alan Budney; Amanda Gruber; Nady el-Guebaly
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

Review 8.  Treatment of Cannabis Use Disorder: Current Science and Future Outlook.

Authors:  Brian J Sherman; Aimee L McRae-Clark
Journal:  Pharmacotherapy       Date:  2016-05       Impact factor: 4.705

9.  Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.

Authors:  Jack R Cornelius; Tammy Chung; Christopher Martin; D Scott Wood; Duncan B Clark
Journal:  Addict Behav       Date:  2008-02-11       Impact factor: 3.913

Review 10.  Use of dronabinol for cannabis dependence: two case reports and review.

Authors:  Frances R Levin; Herbert D Kleber
Journal:  Am J Addict       Date:  2008 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.